Justin Chickles, CEO & Co-Founder of Glycyx Therapeutics

from Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere · host Julio G. Martinez-Clark

Could opioids be silently undermining cancer immunotherapy?This week, Justin Chickles — CEO and co-founder of Glycyx Therapeutics — explains how his team is tackling this overlooked challenge with axelopran, a breakthrough therapy now advancing to Phase 2 trials.From his early career at Johnson & Johnson to leading multiple startups, Justin offers a rare, insider’s perspective on driving biotech innovation from concept to clinic. If you’re interested in cutting-edge oncology, translational science, and biotech entrepreneurship, you won’t want to miss this episode.

Episode metadata supplied by the publisher feed · Published Aug 15, 2025

Embed this episode

Attribution link and audio player

Ready to play

Justin Chickles, CEO & Co-Founder of Glycyx Therapeutics

0:00 40:12

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere?

This episode is 40 minutes long.

When was this Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere episode published?

This episode was published on August 15, 2025.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!